Opendata, web and dolomites

ENTRANCE SIGNED

Developing the iTOP kit: Empowering scientists with efficient intracellular delivery of biologicals in hard-to-manipulate cell types

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENTRANCE project word cloud

Explore the words cloud of the ENTRANCE project. It provides you a very rough idea of what is the project "ENTRANCE" about.

wo2015028969    lines    developers    human    move    transfect    line    investments    leader    biomedically    active    dna    2020    standard    diseases    difficult    journal    possibilities    proper    ambition    notoriously    scientifically    sme    forecasted    mammalian    team    innovative    generously    bioactive    efficient    biologically    entry    stimulate    inside    forum    significantly    itop    kit    pipeline    market    extremely    molecules    biomolecules    pace    expand    create    fte    models    types    revolution    empowering    direct    back    validated    tool    manipulate    interactive    rna    cell    combinations    efficiency    2015    unprecedented    immense    scientific    latter    published    instigate    patented    community    immortalized    merits    ruo    underpin    unmet    earn    buzz    accelerated    bv    16    sharing    proteins    therapeutic    entrance    technologies    experiences    biomedical    stem    marketing    drug    ntrans    sciences    genetic    cells    primary   

Project "ENTRANCE" data sheet

The following table provides information about the project.

Coordinator
NTRANS TECHNOLOGIES BV 

Organization address
address: UPPSALALAAN 8
city: UTRECHT
postcode: 3584 CT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.ntranstechnologies.com/entrance/
 Total cost 1˙514˙200 €
 EC max contribution 1˙514˙200 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NTRANS TECHNOLOGIES BV NL (UTRECHT) coordinator 1˙514˙200.00

Map

 Project objective

NTrans Technologies BV has developed iTOP; a novel and extremely effective method to deliver highly relevant bioactive molecules (including DNA, RNA, active proteins, and their combinations) into mammalian cells. This includes the efficient delivery of such molecules inside the most biologically and biomedically relevant cell types (e.g. human primary and stem cells), which are notoriously difficult to manipulate. iTOP technology has been scientifically validated (published in the top scientific journal Cell in 2015) and patented (WO2015028969).

iTOP addresses the unmet need of researchers and drug developers to be able to transfect a range of biomolecules into biologically relevant cell models; in particular to study genetic diseases and to underpin results obtained with standard immortalized cell lines.

The ENTRANCE project includes the necessary steps towards market entry of the iTOP research-use-only (RUO) kit: The development of (i) an iTOP RUO kit and (ii) an iTOP on-line community as innovative marketing tool that will support proper use and stimulate efficient application of the technology. The ENTRANCE project will thus provide the scientific community access to the novel iTOP tool, facilitate direct access of iTOP kit users to the NTrans support team, and enable sharing of user experiences via an iTOP interactive forum.

ENTRANCE will instigate a revolution in biomedical sciences by empowering both researchers and drug developers to manipulate the most relevant cell types with unprecedented efficiency. This will allow the field to move forward at a significantly accelerated pace.

The iTOP RUO kit will generously earn back the investments within 4 years, and help to create a buzz around the merits and possibilities of the technology. The latter is of immense value to the SME forecasted to support 16 FTE by 2020, with the ambition to expand its product pipeline and become leader in technologies for delivery of therapeutic biomolecules into primary cells.

 Deliverables

List of deliverables.
3.4b iTOP community platform completed Websites, patent fillings, videos etc. 2020-03-24 11:33:03
1.5b First lot of sample kit produced Demonstrators, pilots, prototypes 2020-02-27 15:22:05
1.3 Digital user manuals completed Documents, reports 2020-02-27 15:21:52
3.5b Final version of the DMP Documents, reports 2019-07-30 13:59:42
3.1b Report of the Mid-Term event Documents, reports 2019-05-31 11:55:55
3.3a Dedicated web pages for ENTRANCE Websites, patent fillings, videos etc. 2019-05-31 11:55:51
3.1a Report of the Kick-off Event Documents, reports 2019-05-31 11:55:52
3.5a First version of DMP Documents, reports 2019-05-31 11:56:04

Take a look to the deliverables list in detail:  detailed list of ENTRANCE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENTRANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENTRANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More